报价延迟最少15分钟:2025/07/20 13:11 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
14.54 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.71/-0.66
|
|
企业价值
1.35B
|
| 资产负债 |
|
每股账面净值
0.58
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
14.00M
|
|
每股收益
0.21
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/07/20 13:11 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer. |
